Targeting a specific cell death process in aggressive lung cancer types
Targeting ferroptosis in aggressive subtypes of lung cancer
This study is looking at ways to help people with a specific type of lung cancer that has certain gene mutations, by finding new treatments that can make the cancer cells die off more effectively, which could improve their overall care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11133425 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for patients with a specific type of non-small cell lung cancer (NSCLC) that has mutations in the STK11 and KEAP1 genes. The study investigates how these mutations allow cancer cells to evade a form of cell death known as ferroptosis, which is crucial for controlling tumor growth. By using advanced techniques like CRISPR/Cas9, the researchers aim to identify new therapeutic strategies that can induce ferroptosis in these resistant cancer cells, potentially enhancing the effectiveness of existing treatments. The goal is to better understand the mechanisms behind this resistance and develop targeted therapies that can overcome it.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with STK11/KEAP1 co-mutant non-small cell lung cancer.
Not a fit: Patients with other types of lung cancer or those without the STK11/KEAP1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for patients with aggressive lung cancer.
How similar studies have performed: While targeting ferroptosis is a relatively novel approach, preliminary studies have shown promise in similar cancer types, indicating potential for success.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Sen, Triparna — Icahn School of Medicine at Mount Sinai
- Study coordinator: Sen, Triparna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.